Pharmaceuticals

Tresiba® Demonstrated Lower Day-to-Day and Within-Day Variability in Glucose-Lowering Effect Compared With Insulin Glargine U300

BAGSVÆRD, Denmark, Nov. 12, 2016 /PRNewswire/ -- This material is intended for global medical media only.   For journalistic assessment and preparation before publication.   Results from a study comparing the pharmacodynamics of Tresiba® (insulin degludec) with insulin glargine U300 in people w...

2016-11-12 16:00 1809

Sanofi Presented Full Results of a PK/PD Study Comparing Toujeo(R) to Insulin Degludec in People With Type 1 Diabetes

PARIS, Nov. 11, 2016 /PRNewswire/ -- - Toujeo® provides a flatter profile than insulin degludec with less within- day fluctuations -  Sanofi presented today the full results of a pharmacokinetic / pharmacodynamic (PK/PD) study with Toujeo® (insulin glargine 300 Units/mL...

2016-11-11 23:00 1676

Japan's AstaReal Aims to Grow ASEAN Presence, Sets Up First Asian Branch in Singapore

SINGAPORE, Nov. 3, 2016 /PRNewswire/ -- Japan-based AstaReal Group marks the 70th anniversary of its parent company, Fuji Chemical Industries, with the establishment of its first Asian branch outside ofJapan: AstaReal Pte Ltd Singapore. Having committed over 20 years into the research and develo...

2016-11-03 19:36 2130

HK Bio-medical Start-up Launches Budget-friendly Diabetes Risk Profiling

HONG KONG, Nov. 3, 2016 /PRNewswire/ -- Hong Kong biomedical start-up GemVCare today launches quick and budget-friendly genetic tests for identifying the risk of diabetes onset for individuals. The solution came after 20 years of studying the genetic links of diabetes by the Hong Kong Science...

2016-11-03 19:01 2365

Pharma in Indonesia: Competing for Higher Margins

JAKARTA, Nov. 2, 2016 /PRNewswire/ -- IPMG members - including Novartis, Merck, Bayer, Boehringer Ingelheim, and Pfizer -have invested more than USD $1 billion inIndonesia's pharmaceutical industry over the past few years, particularity for the construction of factories and clinical research (sou...

2016-11-02 15:00 1542

Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (PedPRM) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD)

TEL AVIV, Israel, Nov. 2, 2016 /PRNewswire/ -- Neurim Pharmaceuticals ("Neurim") announced today top-line results from its NEU_CH_7911 Phase III study. PedPRM met the primary efficacy endpoint demonstrating statistically significant improvement in total sleep time (TST) ...

2016-11-02 09:00 1791

Celgene and IBM Watson Health Forge Collaboration Designed to Transform Patient Safety Monitoring

SUMMIT, New Jersey and CAMBRIDGE, Massachusetts, Nov. 2, 2016 /PRNewswire/ -- Celgene Corporation (NASDAQ: CELG) and IBM Watson Health (NYSE:IBM ) today announced a collaboration to co-develop IBM Watson for Patient Safety, a new offering that aims to enhance pharmac...

2016-11-02 04:30 1873

Takeda Unmasks Four New Super Heroes at London's Comic Con to Highlight the Strength of those Living with Inflammatory Bowel Disease (IBD) with the Support of Marvel Custom Solutions

OSAKA, Japan, Oct. 28, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502 ) along with the support of Marvel Custom Solutions today announces the launch of four new Super Hero characters and the first chapter of a new graphic comic...

2016-10-28 16:05 1917

Pharmaceutical Sector: Opportunities for IT, Microelectronics, Cancer Screening and Smart Packaging

LONDON, Oct. 27, 2016 /PRNewswire/ -- In healthcare, there is a paradigm shift from a fee-for-service model towardvalue-based care. It is disrupting the business models and creating opportunities forpharmaceutical sector as well. Pharma companies are looking beyond sales of blockbuster drugs, and...

2016-10-27 18:06 1279

Mundipharma Launches Step-change Cancer Care Medicine Akynzeo(R) in Singapore

SINGAPORE, Oct. 27, 2016 /PRNewswire/ -- Akynzeo® has been approved for use in Singapore to prevent CINV. Without appropriate antiemetic prophylaxis 70-80% of all cancer patients receiving chemotherapy experience nausea and/or vomiting.1 Akynzeo® is a combination of netupitant (highly-selective ...

2016-10-27 13:03 1868

InClinica and IC LifeSciences Launch Regional Office in Malaysia

KUALA LUMPUR, Malaysia, Oct. 27, 2016 /PRNewswire/ -- InClinica, a contract Clinical Research Organisation (CRO) headquartered inPhiladelphia, USA and its subsidiary company, IC LifeSciences launched theirAsia Pacific office in Kuala Lumpur recently. The regional office located at Menara KH will ...

2016-10-27 08:00 3408

Teva Pharmaceuticals and IBM Expand Global Partnership to Enable Drug Development and Chronic Disease Management with Watson

LAS VEGAS, Oct. 26, 2016 /PRNewswire/ -- IBM (NYSE:IBM ) and Teva Pharmaceutical Industries Ltd ., (NYSE and TASE: TEVA) today announced a significant expansion of their existing global e-Health alliance with a focus on two key healthcare c...

2016-10-26 19:00 1659

Plasma Protein Therapeutics Association Participates in U.S. Trade Mission to China

ANNAPOLIS, Maryland, Oct. 26, 2016 /PRNewswire/ -- The Plasma Protein Therapeutics Association (PPTA), the standard setting and global advocacy organization that represents plasma donation centers and manufacturers of plasma protein therapies, was chosen through a highly-selective vetting process...

2016-10-26 06:00 1759

Athenex and Beijing Sciecure Pharmaceutical announce binding agreement to launch and market five injectable pharmaceutical products in North America

BUFFALO, New York and HONG KONG, Oct. 25, 2016 /PRNewswire/ -- Athenex Pharmaceutical Division and Beijing Sciecure Pharmaceutical Co., Ltd., a specialty pharmaceutical company, today announced a binding agreement to launch and market 5 pharmaceutical products, all injectable, in theNorth America...

2016-10-25 22:24 1905

ADI-PEG 20 Can Boost Anti-Tumor Immune Surveillance

SAN DIEGO, Oct. 25, 2016 /PRNewswire/ -- Polaris Group announced today that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can boost anti-tumor immune surveillance according to research presented by Polaris at the 2016 American Association for Cancer Research Tumor Immunology...

2016-10-25 03:55 2062

MicuRx Initiates Phase 3 Clinical Trial for MRX-I, A New Potent Oral Antibiotic Against Gram-positive Bacteria, Including MRSA

HAYWARD, Calif. and SHANGHAI, Oct. 20, 2016 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc. announced today that it has initiated patient enrollment in a pivotal Phase 3 study of MRX-I inChina for the treatment of complicated skin and skin structure infections (cSSSI). These infections are frequentl...

2016-10-20 08:00 1912

First Patient in Malaysia Receives TheraSphere™ radioembolisation Therapy

LONDON, Oct. 19, 2016 /PRNewswire/ -- BTG plc (LSE: BTG), an international specialist healthcare company, today announced that the first patient inMalaysia was treated with TheraSphere™ - a transarterial radioembolisation (TARE) therapy, which targets primary liver cancer and metastatic colorec...

2016-10-19 07:30 2006

Athenex announces Xiangxue Pharmaceuticals Company Limited, its KX-02 development partner in China, has achieved a regulatory milestone in that territory

BUFFALO, New York, Oct. 18, 2016 /PRNewswire/ -- Athenex today announced that its development partner for KX-02, Xiangxue Pharmaceuticals Company Limited, has publicized that the Guangdong Province Food and Drug Administration (FDA) declared completion of the Investigational New Drug (IND) applic...

2016-10-18 23:23 1615

Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies

OSAKA, Japan, Oct. 17, 2016 /PRNewswire/ -- Takeda Pharmaceutical Company Limited [TSE: 4502], ("Takeda") is presenting data on the real-world effectiveness and safety of vedolizumab in patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) during the United ...

2016-10-17 14:00 1646

CHMP Adopts Positive Opinion of Metformin, Including Merck's Type 2 Diabetes Treatment Portfolio, in Patients with Renal Impairment

DARMSTADT, Germany, Oct. 14, 2016 /PRNewswire/ -- Not intended for U.S. and UK-based media  * Metformin receives positive CHMP opinion for treatment of type 2 diabetes patients with moderate renal impairment (CKD stage 3), which will lead to extended treatment access   * As the metformin or...

2016-10-14 22:53 1554
1 ... 96979899100101102 ... 127